var data={"title":"Triamterene nephrotoxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Triamterene nephrotoxicity</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Gary C Curhan, MD, ScD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Stanley Goldfarb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">Triamterene</a> is a potassium-sparing diuretic that is commonly used in the treatment of hypertension in combination with a thiazide diuretic. It is not widely appreciated, however, that triamterene is a potential nephrotoxin, occasionally inducing crystalluria and cast formation, and rarely causing stone formation or reversible acute kidney injury [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CRYSTALLURIA AND CAST FORMATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">Triamterene</a> can induce the formation of both triamterene crystals (which are usually brown in color, spherical, and appear as a &quot;Maltese cross&quot; under polarized light) and granular casts (which can look identical to brown pigmented casts), at least when used in higher doses. The following studies illustrate this effect:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 20 healthy adults who ingested 100 mg of <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a>, all 20 excreted triamterene crystals, and 17 out of 20 excreted granular casts, which were present within 11 hours of taking the drug [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/3\" class=\"abstract_t\">3</a>]. Alkalinization of the urine to a pH of 7.5 or higher prevented the appearance of crystals. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 26 hypertensive patients given 50 mg of <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a>, crystals and casts were seen in 14 (54 percent) [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p>Whether crystals and casts commonly occur with 37.5 mg of <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a> (a more typical dose) is unknown. The mechanism responsible for the cast formation is unclear but appears to be specific to triamterene, as this finding is not seen with <a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">amiloride</a>, another potassium-sparing diuretic [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/3,4\" class=\"abstract_t\">3,4</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">TRIAMTERENE STONES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Stone formation is an uncommon complication of <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a> therapy [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/2,5-7\" class=\"abstract_t\">2,5-7</a>]. One study, for example, found that triamterene was present in 1 in every 200 to 250 stones [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/6,8\" class=\"abstract_t\">6,8</a>]. Most of these stones contained both triamterene and calcium oxalate or uric acid, although pure triamterene stones did occur [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/6,9\" class=\"abstract_t\">6,9</a>]. Of course, the proportion of all stones containing triamterene will depend upon how commonly triamterene is used in the general population. In addition, the incidence of triamterene-containing stones may be decreasing [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Patients who form <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a>-containing stones are more likely to have a prior history of stone disease, suggesting that metabolic predisposition is an important risk factor [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=risk-factors-for-calcium-stones-in-adults\" class=\"medical medical_review\">&quot;Risk factors for calcium stones in adults&quot;</a>.) </p><p><a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">Triamterene</a> stones are faintly opaque on X-ray examination and, like other stones, are easily seen with non-contrasted computed tomography. (See <a href=\"topic.htm?path=diagnosis-and-acute-management-of-suspected-nephrolithiasis-in-adults#H10\" class=\"medical medical_review\">&quot;Diagnosis and acute management of suspected nephrolithiasis in adults&quot;, section on 'Diagnostic imaging'</a>.)</p><p>Early studies suggested no relation with urine pH, but later studies found that <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a> crystals are not seen when the urine pH is 7.5 or higher. If triamterene crystals are seen, the medication should be stopped. <a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">Amiloride</a> is an alternative potassium-sparing agent that does not form crystals in the urine.</p><p><a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">Triamterene</a> stones cannot be dissolved by raising the urine pH and should be treated by conventional urologic techniques [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ACUTE KIDNEY INJURY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversible acute kidney injury is another rare problem with <a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">triamterene</a> (but not other potassium-sparing diuretics). Two different mechanisms have been described: intratubular obstruction by crystals and concurrent therapy with a nonsteroidal anti-inflammatory drug [<a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/12-14\" class=\"abstract_t\">12-14</a>]. Why triamterene seems to make the patient more sensitive to NSAIDs than other diuretics is not clear. (See <a href=\"topic.htm?path=nsaids-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">&quot;NSAIDs: Acute kidney injury (acute renal failure)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20367461\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=triamterene-drug-information\" class=\"drug drug_general\">Triamterene</a>, a commonly used potassium-sparing diuretic, may produce crystalluria and granular casts in as many as one-half of patients, sometimes leading to nephrolithiasis or acute kidney injury. In patients taking triamterene, the medication should be discontinued if crystals or casts are seen in the urine or if triamterene is reported as a component of a stone. <a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">Amiloride</a> is a safe alternative. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/1\" class=\"nounderline abstract_t\">Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989; 51:454.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/2\" class=\"nounderline abstract_t\">Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/3\" class=\"nounderline abstract_t\">Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 1986; 26:169.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/4\" class=\"nounderline abstract_t\">Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet 1985; 2:73.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/5\" class=\"nounderline abstract_t\">Woolfson RG, Mansell MA. Does triamterene cause renal calculi? BMJ 1991; 303:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/6\" class=\"nounderline abstract_t\">Carr MC, Prien EL Jr, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144:1339.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/7\" class=\"nounderline abstract_t\">Sabot JF, Bornet CE, Favre S, Sabot-Gueriaux S. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283:151.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/8\" class=\"nounderline abstract_t\">Ettinger B, Oldroyd NO, S&ouml;rgel F. Triamterene nephrolithiasis. JAMA 1980; 244:2443.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/9\" class=\"nounderline abstract_t\">S&ouml;rgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134:871.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/10\" class=\"nounderline abstract_t\">Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004; 64:245.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/11\" class=\"nounderline abstract_t\">Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol 2003; 5:227.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/12\" class=\"nounderline abstract_t\">Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982; 96:317.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/13\" class=\"nounderline abstract_t\">Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40:216.</a></li><li><a href=\"https://www.uptodate.com/contents/triamterene-nephrotoxicity/abstract/14\" class=\"nounderline abstract_t\">Nasr SH, Milliner DS, Wooldridge TD, Sethi S. Triamterene crystalline nephropathy. Am J Kidney Dis 2014; 63:148.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7365 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20367461\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CRYSTALLURIA AND CAST FORMATION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">TRIAMTERENE STONES</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">ACUTE KIDNEY INJURY</a></li><li><a href=\"#H20367461\" id=\"outline-link-H20367461\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-acute-management-of-suspected-nephrolithiasis-in-adults\" class=\"medical medical_review\">Diagnosis and acute management of suspected nephrolithiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">NSAIDs: Acute kidney injury (acute renal failure)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-factors-for-calcium-stones-in-adults\" class=\"medical medical_review\">Risk factors for calcium stones in adults</a></li></ul></div></div>","javascript":null}